SmithKline emphasizing Tagamet HB prescription heritage in early promotional materials.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE EMPHASIZING TAGAMET HB's PRESCRIPTION HERITAGE and its long marketing history as the first H2 antagonist in promotional materials announcing FDA's June 19 approval of the Rx-to-OTC switch for heartburn treatment. The company pointed out, for example, that Tagamet HB represents the "largest Rx-to-OTC conversion in U.S. pharmaceutical history," noting that "in the U.S. alone, more than 200 mil. Tagamet prescriptions have been filled."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning